Ingrid Garajová
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Year:
2026
Year:
2026
Year:
2026
Pancreatic ductal adenocarcinoma remains associated with a poor prognosis, even when diagnosed at an early stage. Consequently, it is imperative to carefully consider the available therapeutic options and tailor them based on clinically relevant biomarkers. In our comprehensive review, we specifically concentrated on the identification of novel predictive and prognostic markers that have the potential to be integrated into multiparametric scoring systems. These scoring systems aim to accurately predict the efficacy of neoadjuvant chemotherapy in surgically resectable pancreatic cancer cases. By identifying robust predictive markers, we can enhance our ability to select patients who are most likely to benefit from neoadjuvant chemotherapy. Furthermore, the identification of prognostic markers can provide valuable insights into the overall disease trajectory and inform treatment decisions. The development of multiparametric scoring systems that incorporate these markers holds great promise for optimizing the selection of patients for neoadjuvant chemotherapy, leading to improved outcomes in resectable pancreatic neoplasia. Continued research efforts are needed to validate and refine these markers and scoring systems, ultimately advancing the field of personalized medicine in pancreatic adenocarcinoma management.
Year:
2023
Collaborators (22)
Jeroen Dekervel
-
Fabian Finkelmeier
University Hospital Frankfurt
Stephen Chan
The Chinese University of Hong Kong (CUHK)
LUCA MORELLI
Professore Associato in Chirurgia Generale
University of Pisa
David J. Pinato
Imperial College London
Mario Scartozzi
-
Hong Jae Chon
Associate Professor
CHA Bundang Medical Center
Elisa Giovannetti
-
Salvatore Corallo
Researcher
University of Pavia
Fabio Gelsomino
-
ilhwan kim
Associate Professor
Inje University Ilsan Paik Hospital
Jin Won Kim
Professor
Seoul National University Hospital
Giovanni Farinea
University of Turin
Antonio Avallone
Chief of DH Chemotherapy
Fondazione IRCCS Istituto Nazionale dei Tumori
Sara Lonardi
Head of Dept
Istituto Oncologico Veneto
Matteo Landriscina
Professor of Medical Oncology
Università degli Studi di Foggia
Chiara Braconi
Chair in HepatoBiliary Oncology
University of Glasgow
Monica Niger
Fondazione IRCCS Istituto Nazionale dei Tumori
Lorenzo Antonuzzo
University of Florence
Lorenza Rimassa
Head of Hepatopancreatobiliary Oncology Unit
Humanitas University
Andrea Cavazzoni
Assistant professor
University of Parma
Arndt Vogel
Hannover Medical School
Make your next move.
Prepare your application
Review drafts before you send them.